Marin F. Xavier, MD

Articles by Marin F. Xavier, MD

Increasing CAR T-cell Use in R/R DLBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD

January 17th 2022

Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.

CAR T or Transplant in DLBC Lymphoma: John M. Burke, MD; Marin F. Xavier, MD

ByJohn M. Burke, MD,Marin F. Xavier, MD

November 20th 2021

Experts discussed using newer targeted treatment approaches as frontline therapy instead of transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.

CD19 CAR T and Therapies in LBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD

ByJohn M. Burke, MD,Marin F. Xavier, MD

November 18th 2021

Experts discussed using CD19-targeted agents in patients with various subtypes of diffuse large B-cell lymphoma.

Marin F. Xavier, MD

Articles by Marin F. Xavier, MD

Increasing CAR T-cell Use in R/R DLBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD

CAR T or Transplant in DLBC Lymphoma: John M. Burke, MD; Marin F. Xavier, MD

CD19 CAR T and Therapies in LBC Lymphoma: Marin F. Xavier, MD; John M. Burke, MD

Latest Updated Articles

Trending on CGTlive®

Regeneron’s Gene Therapy DB-OTO Improves Speech Perception in Children With Otoferlin-Related Hearing Loss

Myrtelle’s Canavan Disease Gene Therapy Effects Significant Decrease in CSF NAA and Increases in Brain Myelin Volume